🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Immune Deficiencies

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders NCT07850284n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis NCT06699394NA2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Teclistamab (Tec) Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers NCT05395624Phase 1, Phase 23 sites📍 San Francisco📍 Stanford📍 Jacksonville Ashvattha Therapeutics, Inc. · Tests: 18F-OP-801 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites📍 Orange📍 Denver📍 Coral Springs CSL Behring · Tests: IgPro20 Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis NCT06971380Phase 21 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART Promoting Diagnosis and Management of AL in Italy (ProDigALIty) NCT06383143n/a4 sites📍 Bari📍 Catania📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: no intervention Studies of Disorders With Increased Susceptibility to Fungal Infections NCT01222741n/a1 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… Essen Amyloidosis Registry NCT06887283n/a1 site📍 Essen University Hospital, Essen Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load NCT06974877Phase 11 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… · Tests: 124I AT-01 Collection of Samples and Clinical Data From Patients With Amyloid Diseases NCT00898235n/a1 site📍 Boston Boston Medical Center · Tests: clonality analysis, polymerase chain reaction, protein analysis, biologic sample preservation procedure, laboratory bio… Rapid dFLC Response Predict CHR in AL Amyloidosis NCT06627309n/a8 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Dara IV, Bortezomib (drug), Dexamethasone, Cyclophosphamide (CTX), Dara SC Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD NCT06418477Phase 23 sites📍 Beijing📍 Beijing📍 Guangzhou Peking University People's Hospital · Tests: Dara-CyBorD Screening for AL Amyloidosis in Smoldering Multiple Myeloma NCT06365060n/a13 sites📍 Birmingham📍 Los Angeles📍 San Francisco Tufts Medical Center Daratumumab for Patients With Light Chain Amyloidosis NCT06376214NA1 site📍 Nanjing Nanjing University School of Medicine · Tests: Dratumumab / Hyaluronidase Injection [Darzalex Faspro], Pomalidomide 4 MG, autologous stem cell transplantation (ASCT) Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases NCT00874783n/a1 site📍 Jerusalem Hadassah Medical Organization A Registry of AL Amyloidosis (ReAL) NCT04839003n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis NCT06342466Phase 21 site📍 Beijing Jin Lu, MD · Tests: Bortezomib, Pomalidomide, Dexamethasone A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993n/a1 site📍 Beijing Peking University First Hospital · Tests: No intervention A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis NCT05652335Phase 129 sites📍 Duarte📍 Irvine📍 San Francisco Janssen Research & Development, LLC · Tests: JNJ-79635322 ALS Research Collaborative NCT06885918n/a1 site📍 Watertown ALS Therapy Development Institute Detection and Characterization of Infections and Infection Susceptibility NCT00404560n/a1 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas NCT07285044Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cancer Therapeutic Procedure, Cancer Therapeutic Procedure, Questionnaire Administration The Norwegian Immunotherapy in Multiple Myeloma Study NCT06855121n/a23 sites📍 Arendal📍 Ålesund📍 Bergen St. Olavs Hospital · Tests: Teclistamab, Elranatamab, Ciltacabtagene Autoleucel, Talquetamab, Idecabtagene vicleucel Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis NCT07250269Phase 19 sites📍 Beijing📍 Beijing📍 Beijing Gracell Biotechnologies (Shanghai) Co., Ltd. · Tests: GC012F Injection Hungarian National Systemic Amyloidosis Registry NCT07689331n/a12 sites📍 Balatonfüred📍 Budapest📍 Budapest Semmelweis University A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) NCT06205953n/a6 sites📍 Heidelberg📍 Pavia📍 Utrecht Fondazione IRCCS Policlinico San Matteo di Pavia Evaluation of Skin Tests in Biotherapy Allergies NCT06971848NA1 site📍 Angers University Hospital, Angers · Tests: Drug skin tests (investigating hypersensitivity to a biotherapy) Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies NCT07251179n/a1 site📍 Strasbourg University Hospital, Strasbourg, France · Tests: blood draw
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy